Index of medicine substances

Rimonabant  •  Alimentary tract and metabolism | Antiobesity preparations, excl. diet products | Other antiobesity drugs (A08AX01)

Riociguat  •  Cardiovascular system | Other antihypertensives | Antihypertensives for pulmonary arterial hypertension (C02KX05)

Ripretinib  •  Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors (L01EX19)

Risankizumab  •  Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Interleukin inhibitors (L04AC18)

Risdiplam  •  Musculo-skeletal system | Other drugs for disorders of the musculo-skeletal system | Other drugs for disorders of the musculo-skeletal system (M09AX10)

Risedronate + calcium + cholecalciferol  •  Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates, combinations (M05BB04)

Risedronic acid  •  Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates (M05BA07)

Risperidone  •  Nervous system | Antipsychotics | Other antipsychotics (N05AX08)

Ritlecitinib  •  Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Janus-associated kinase (JAK) inhibitors (L04AF08)

Ritonavir  •  Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors (J05AE03)

Rituximab  •  Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Cd20 (clusters of differentiation 20) inhibitors (L01FA01)

Rivaroxaban  •  Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Direct factor xa inhibitors (B01AF01)

Rivaroxaban + acetylsalicylic acid  •  Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Direct factor xa inhibitors (B01AF51)

Rivastigmine  •  Nervous system | Anti-dementia drugs | Anticholinesterases (N06DA03)

Rizatriptan  •  Nervous system | Antimigraine preparations | Selective serotonin (5HT1) agonists (N02CC04)

Rocuronium bromide  •  Musculo-skeletal system | Muscle relaxants | Muscle relaxants, peripherally acting agents | Other quaternary ammonium compounds (M03AC09)

Roflumilast  •  Respiratory system | Other systemic drugs for obstructive airway diseases (R03DX07)

Rolitetracycline + chloramphenicol + colistin  •  Sensory organs | Antiinfectives | Antibiotics (S01AA30)

Romiplostim  •  Blood and blood forming organs | Vitamin k and other hemostatics | Other systemic hemostatics (B02BX04)

Romosozumab  •  Musculo-skeletal system | Drugs affecting bone structure and mineralization | Other drugs affecting bone structure and mineralization (M05BX06)

Ropeginterferon alfa 2B  •  Antineoplastic and immunomodulating agents | Immunostimulants | Immunostimulants | Interferons (L03AB15)

Ropinirole  •  Nervous system | Dopaminergic agents | Dopamine agonists (N04BC04)

Ropivacaine  •  Nervous system | Anesthetics | Anesthetics, local | Amides (N01BB09)

Rosiglitazone  •  Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Thiazolidinediones (A10BG02)

Rosiglitazone + glimepiride  •  Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs (A10BD04)

Rosiglitazone + metformin  •  Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs (A10BD03)

Rosuvastatin  •  Cardiovascular system | Lipid modifying agents | Lipid modifying agents, plain | Hmg coa reductase inhibitors (C10AA07)

Rosuvastatin + amlodipine  •  Cardiovascular system | Lipid modifying agents | Lipid modifying agents, combinations | Lipid modifying agents in combination with other drugs (C10BX09)

Rosuvastatin + amlodipine + perindopril  •  Cardiovascular system | Lipid modifying agents | Lipid modifying agents, combinations | Lipid modifying agents in combination with other drugs (C10BX14)

Rosuvastatin + ezetimibe  •  Cardiovascular system | Lipid modifying agents | Lipid modifying agents, combinations | Combinations of various lipid modifying agents (C10BA06)